<DOC>
	<DOCNO>NCT01367808</DOCNO>
	<brief_summary>Variability drug response due either pharmacokinetic pharmacodynamic factor . The reason people differ pharmacokinetics pharmacodynamics manifold include , e.g. , genetic factor , disease , age concomitantly administer drug . Oxidation reaction dominant metabolism drug cytochrome P-450 enzyme ( CYP ) recognize chief contributor . We previously show drug interaction mediate inhibition CYP enzymes may major clinical significance . This study aim examine possible interaction low-dose sublingual buprenorphine posaconazole voriconazole . The study conduct use randomize , balance cross-over design three phase . Twelve male female adult non-smoking subject age 18-40 year body weight within ±15 % ideal weight height recruit study . The subject submit physical examination , determination previous present chronic disease , comprehensive laboratory test ascertain good health . The subject fill modify Finnish version Abuse Questions ass vulnerability opioid abuse . Laboratory screen include CBC ( include hemoglobin , hematocrit , differential WBC , platelet count ) , SGOT , SGPT , alkaline phosphatase , BUN creatinine , woman pregnancy test . Urine screen glucose , proteins drug addiction potential . Blood pressure sit position must within normal limit . Base line ECG must normal . The subject give randomized , cross-over , balanced manner interval four week either placebo , vorikonazole posakonazole . On day 5 , challenge dose 0.4 0.6 mg sublingual buprenorphine ( Temgesic , Schering-Plough ) administer 11.00 , i.e . 1 h last dose placebo , voriconazole posaconazole . The dose 0.6 mg placebo 0.4 mg posaconazole voriconazole . If necessary , naloxone ( Naloxone B. Braun , Braun ) give sufficient dos counteract severe adverse effect buprenorphine . For nausea vomiting , intravenous tropisetron use , need . On day 4 , forearm vein cannulate plastic cannula blood sampling . Timed venous blood sample draw administration buprenorphine 0.5 , 1 , 1.5 , 2 , 3 , 4 , 5 , 6 , 8 , 10 , 12 18-20 hour administration . Another venous cannula insert opposite forearm intravenous administration naloxone . Urine collect 18-20 hour . The psychomotor effect buprenorphine assess visual analog scale ( Bond Lader 1974 ) digit symbol substitution test ( Stone 1984 ) 1-2 hour interval 12 hour buprenorphine administration . Visual analogue scale use follow item : alert / drowsy , good / poor performance , / strong drug effect , unpleasant /pleasant feeling , / extreme nausea . For pharmacodynamic variable , area response-time curve determine trapezoidal rule 12 hour . The analgesic effect buprenorphine evaluate use cold pressor test .</brief_summary>
	<brief_title>Effects Posaconazole Voriconazole Pharmacokinetics Pharmacodynamics Sublingual Buprenorphine</brief_title>
	<detailed_description />
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Healthy volunteer Age 1840 Body weight within ±15 % ideal weight height A previous history intolerance study drug related compound additives Concomitant drug therapy kind least 14 day prior study Existing recent significant disease History hematological , endocrine , metabolic gastrointestinal disease , include gut motility disorder History asthma kind drug allergy Previous present alcoholism , drug abuse , psychological emotional problem likely invalidate inform consent , limit ability subject comply protocol requirement A positive test result urine toxicology A `` yes '' answer one Abuse Questions Pregnancy nurse Donation blood 4 week prior study Special diet life style condition would compromise condition study interpretation result Participation study involve investigational market drug product concomitantly within one month prior entry study Smoking one month start study whole study period Any history coagulation abnormality , also first degree relative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Buprenorphine</keyword>
	<keyword>Vorikonazole</keyword>
	<keyword>Posakonazole</keyword>
	<keyword>Interactions</keyword>
</DOC>